These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27453983)

  • 1. Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy.
    Kim Y; Park YH; Lee JY; Choi IY; Yu H
    BMC Med Inform Decis Mak; 2016 Jul; 16 Suppl 1(Suppl 1):63. PubMed ID: 27453983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.
    Berg KD; Røder MA; Thomsen FB; Vainer B; Gerds TA; Brasso K; Iversen P
    Prostate; 2015 Oct; 75(14):1499-509. PubMed ID: 26053696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exponential rise in prostate-specific antigen (PSA) during anti-androgen withdrawal predicts PSA flare after docetaxel chemotherapy in patients with castration-resistant prostate cancer.
    Han KS; Hong SJ
    Yonsei Med J; 2015 Mar; 56(2):368-74. PubMed ID: 25683983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer.
    Kim M; Lee J; Jeong CW; Ku JH; Kim HH; Kwak C
    Urol Oncol; 2015 May; 33(5):203.e1-9. PubMed ID: 25726498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.
    Lv W; Shang H; Pei X; Chen Y; Xie H; He D; Wang X; Li L
    Int Urol Nephrol; 2017 Jan; 49(1):61-67. PubMed ID: 27837416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors for response to intermittent androgen deprivation (IAD) in prostate cancer cases with biochemical progression after surgery.
    Sciarra A; Cattarino S; Gentilucci A; Alfarone A; Innocenzi M; Gentile V; Salciccia S
    Urol Oncol; 2013 Jul; 31(5):607-14. PubMed ID: 21665494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Prior Local Treatment and Prostate-Specific Antigen Kinetics during Androgen-Deprivation Therapy on the Survival of Castration-Resistant Prostate Cancer.
    Hah YS; Lee JS; Rha KH; Hong SJ; Chung BH; Koo KC
    Sci Rep; 2019 Aug; 9(1):11899. PubMed ID: 31417160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility of prostate-specific antigen in the management of advanced prostate cancer.
    Crawford ED; Bennett CL; Andriole GL; Garnick MB; Petrylak DP
    BJU Int; 2013 Sep; 112(5):548-60. PubMed ID: 23826876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer.
    Tomioka A; Tanaka N; Yoshikawa M; Miyake M; Anai S; Chihara Y; Okajima E; Hirayama A; Hirao Y; Fujimoto K
    BMC Urol; 2014 Apr; 14():33. PubMed ID: 24773608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biomarkers in metastatic castration-resistant prostate cancer].
    Miller K
    Aktuelle Urol; 2015 Jan; 46(1):66-70. PubMed ID: 25658233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First off-time treatment prostate-specific antigen kinetics predicts survival in intermittent androgen deprivation for prostate cancer.
    Sanchez-Salas R; Olivier F; Prapotnich D; Dancausa J; Fhima M; David S; Secin FP; Ingels A; Barret E; Galiano M; Rozet F; Cathelineau X
    Prostate; 2016 Jan; 76(1):13-21. PubMed ID: 26498916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Availability of Local Therapy to Castration-Resistant Prostate Cancer for M0 Patients with Initial Prostate Specific Antigen 100 ng/ml or Higher].
    Kuromoto A; Tanaka T; Koyama J; Goto T; Kimura S; Katsumata Y; Myoen S; Ozawa M; Morozumi K; Sato M; Hoshi S; Numahata K; Arai Y
    Hinyokika Kiyo; 2017 Dec; 63(12):515-520. PubMed ID: 29370662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.
    Naik M; Reddy CA; Stephans KL; Ciezki JP; Garcia J; Grivas P; Stephenson AJ; Klein EA; Tendulkar RD
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):617-23. PubMed ID: 27681757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer.
    Kitagawa Y; Ueno S; Izumi K; Kadono Y; Mizokami A; Hinotsu S; Akaza H; Namiki M
    World J Urol; 2016 Mar; 34(3):319-27. PubMed ID: 26089252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.
    Stewart AJ; Scher HI; Chen MH; McLeod DG; Carroll PR; Moul JW; D'Amico AV
    J Clin Oncol; 2005 Sep; 23(27):6556-60. PubMed ID: 16170163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating high-risk castration resistant prostate cancer (CRPC) using electronic health records.
    Hernandez RK; Cetin K; Pirolli M; Quigley J; Quach D; Smith P; Stryker S; Liede A
    Can J Urol; 2015 Aug; 22(4):7858-64. PubMed ID: 26267023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy and problems of new hormonal agents for the treatment of castration resistant prostate cancer].
    Hakariya T; Sakai H
    Nihon Rinsho; 2016 Jan; 74(1):137-42. PubMed ID: 26793894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.
    Yu EY; Li H; Higano CS; Agarwal N; Pal SK; Alva A; Heath EI; Lam ET; Gupta S; Lilly MB; Inoue Y; Chi KN; Vogelzang NJ; Quinn DI; Cheng HH; Plymate SR; Hussain M; Tangen CM; Thompson IM
    J Clin Oncol; 2015 May; 33(14):1601-8. PubMed ID: 25847934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists.
    Bonde TM; Westerberg M; Aly M; Eklund M; Adolfsson J; Bill-Axelson A; Garmo H; Stattin P; Robinson D
    Scand J Urol; 2022 Jun; 56(3):169-175. PubMed ID: 35548951
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.